How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?

被引:2
|
作者
Aizawa, Keiko [1 ]
Peltier, Daniel [2 ]
Matsuki, Eri [3 ]
Toubai, Tomomi [1 ]
机构
[1] Yamagata Univ, Dept Internal Med 3, Div Hematol & Cell Therapy, Fac Med, 2-2-2 Iida Nishi, Yamagata 9909585, Japan
[2] Univ Michigan, Dept Pediat Hematol Oncol, Med Sch, Ann Arbor, MI USA
[3] Yamagata Univ, Fac Med, Dept Cardiol Pulmonol & Nephrol, Yamagata, Japan
关键词
Transfusion-associated graft-versus-host disease (TA-GVHD); Stem cell transplantation-associated graft-versus-host disease (SCT-GVHD); Acute GVHD; Chronic GVHD; Transfusion; Allogeneic hematopoietic cell transplantation (allo-hct); CONSENSUS DEVELOPMENT PROJECT; INTESTINAL-STEM-CELL; CLINICAL-TRIALS; CRITERIA; RUXOLITINIB; DIAGNOSIS; SURVIVAL; BLOOD; GVHD;
D O I
10.1016/j.transci.2022.103405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare life-threatening complication of blood transfusion caused by donor T cells that escape rejection by the recipient immune system. These donor T cells drive recipient tissue damage in response to host antigens. On the other hand, GVHD occurring after allogeneic hematopoietic cell transplantation (HCT-GVHD) is also caused by donor T cells, but its pathophysiology is more complex and differs due to the effects of tissue damage caused by pre-HCT conditioning and profound immunosuppression. Both TA-GVHD and HCT-GVHD can be fatal; however, mortality is higher with TA-GVHD due to the paucity of treatment options. Here, we compare and summarize the presentation, diagnosis, pathophysiology, prevention, and treatment of TA-GVHD and HCT-GVHD.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] How is transfusion-associated graft-versus-host disease similar to, yet different from, organ transplantation-associated graft-versus-host disease?
    Sato, Naoya
    Marubashi, Shigeru
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2022, 61 (02)
  • [2] Transfusion-associated graft-versus-host disease
    Oto, Ozgur Akin
    Paydas, Semra
    Baslamisli, Fikri
    Tuncer, Ilhan
    Ergin, Melek
    Kalakoc, Emre
    Disel, Umut
    Yavuz, Sinan
    Koese, Fatih
    Tasova, Yesim
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2006, 17 (03) : 151 - 156
  • [3] Transfusion-associated graft-versus-host disease
    Schroeder, ML
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (02) : 275 - 287
  • [4] TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
    RAPPEPORT, JM
    [J]. YALE JOURNAL OF BIOLOGY AND MEDICINE, 1990, 63 (05): : 445 - 454
  • [5] TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
    ORTIZ, A
    CARAMELO, C
    PLAZA, JJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (02): : 128 - 128
  • [6] Transfusion-associated graft-versus-host disease
    Dwyre, D. M.
    Holland, P. V.
    [J]. VOX SANGUINIS, 2008, 95 (02) : 85 - 93
  • [7] TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
    LEBLANC, MH
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 22 (06) : 1121 - 1122
  • [8] Transfusion-associated graft-versus-host disease
    Sunul, Hasibe
    Erguven, Nedret
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2013, 49 (02) : 331 - 333
  • [9] TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
    BRUBAKER, DB
    [J]. HUMAN PATHOLOGY, 1986, 17 (11) : 1085 - 1088
  • [10] TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
    ROCK, CA
    [J]. TRANSFUSION SCIENCE, 1995, 16 (02): : 95 - 95